Skip to content

BridgeBio Pharma BBIO Other Non-Current Assets

Other Non-Current Assets at other companies

Pfizer logo
PfizerPFE
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
ALN
Alnylam PharmaceuticalsALNY
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
Roivant Sciences logo
Roivant SciencesROIV

Other financials

Income statement

See full
Revenue$194.5M+66.8%
Gross profit$184.6M+61.9%
Operating income-$106.0M-1.5%
Net income-$166.6M+1.8%
EPS (diluted)-$0.84+4.5%

Balance sheet

See full
Cash & equivalents$882.0M+62.5%
Total debt$3.3B+32,101%
Total equity-$2.3B-38.2%
Total assets$1.4B+55.5%

Cash flow

See full
Operating cash flow-$197.3M+1.0%
CapEx$69.0K
Free cash flow-$197.3M+0.9%

Valuation

See full
Market cap$12.98B+119%
Enterprise value$15.36B+178%
P/S22.4×-24.1×

Profitability

See full
Gross margin95.1%-0.2pp
Operating margin-90.5%-41.2pp
Net margin-125.9%-54.5pp
FCF margin-76.8%

Returns & leverage

See full
Return on equity-216.8%
Debt / equity
Current ratio1.5×-3.0×

Where this comes from

Reported directly by BridgeBio Pharma in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about BridgeBio Pharma's other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BridgeBio Pharma's other non-current assets?
BridgeBio Pharma (BBIO) reported other non-current assets of $18.62M in Q1 2026.
How has BridgeBio Pharma's other non-current assets changed year-over-year?
BridgeBio Pharma's other non-current assets increased by 12.1% year-over-year, from $16.61M to $18.62M.
What is the long-term trend for BridgeBio Pharma's other non-current assets?
Over 5 years (2020 to 2025), BridgeBio Pharma's other non-current assets has grown at a -6.9% compound annual growth rate (CAGR), from $23.93M to $16.71M.